CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Income Statement [Abstract] | ||||
| Revenue | $ 55,195 | $ 60,750 | $ 111,124 | $ 119,941 |
| Cost of revenue: | ||||
| Cost of revenue exclusive of amortization | 9,418 | 8,800 | 18,773 | 18,941 |
| Amortization | 5,236 | 5,337 | 10,160 | 10,627 |
| Gross profit | 40,541 | 46,613 | 82,191 | 90,373 |
| Operating expenses: | ||||
| Sales and marketing | 19,158 | 20,469 | 38,736 | 41,122 |
| Product development | 6,756 | 7,968 | 13,255 | 17,269 |
| General and administrative | 10,806 | 12,673 | 22,890 | 24,942 |
| Depreciation and amortization | 8,542 | 9,001 | 16,867 | 17,528 |
| Transaction, integration, and restructuring expenses | 2,027 | 672 | 1,262 | 1,937 |
| Goodwill impairment | 0 | 0 | 197,219 | 176,531 |
| Total operating expenses | 47,289 | 50,783 | 290,229 | 279,329 |
| Loss from operations | (6,748) | (4,170) | (208,038) | (188,956) |
| Other income (expense), net: | ||||
| Interest income | 1,253 | 1,749 | 2,550 | 3,801 |
| Interest expense | (2,628) | (2,990) | (5,257) | (5,423) |
| Gain (loss) on remeasurement of Tax Receivable Agreement liability | 64 | (2,901) | 6,585 | 17,763 |
| Loss on partial extinguishment of debt | 0 | 0 | 0 | (507) |
| Other income (expense), net | 262 | (497) | 574 | (1,466) |
| Total other (expense) income, net | (1,049) | (4,639) | 4,452 | 14,168 |
| Net loss before income taxes | (7,797) | (8,809) | (203,586) | (174,788) |
| Benefit from (provision for) income taxes | 345 | (456) | 3,780 | 10,430 |
| Net loss | (7,452) | (9,265) | (199,806) | (164,358) |
| Less: Net loss attributable to noncontrolling interests | (2,030) | (1,714) | (55,763) | (49,579) |
| Net loss attributable to Definitive Healthcare Corp. | $ (5,422) | $ (7,551) | $ (144,043) | $ (114,779) |
| Net loss per share of Class A common stock: | ||||
| Basic | $ (0.05) | $ (0.07) | $ (1.37) | $ (1.05) |
| Diluted | $ (0.05) | $ (0.07) | $ (1.37) | $ (1.05) |
| Weighted average Class A common stock outstanding: | ||||
| Basic | 105,810,516 | 106,815,740 | 105,245,928 | 109,782,640 |
| Diluted | 105,810,516 | 106,815,740 | 105,245,928 | 109,782,640 |
| X | ||||||||||
- Definition Gain (loss) on remeasurement of tax receivable agreement liability. No definition available.
|
| X | ||||||||||
- Definition Transaction, integration and restructuring expenses. No definition available.
|
| X | ||||||||||
- Definition Weighted average earnings per share basic and diluted other disclosures abstract. No definition available.
|
| X | ||||||||||
- Definition Cost of product sold and service rendered, excluding depreciation, depletion, and amortization. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest income earned from interest bearing assets classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of gain (loss) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|